Pfizer Inc (PFE)
Gross profit margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Gross profit | US$ in thousands | 8,904,000 | 47,907,000 | 34,573,000 | 18,171,000 | 21,948,000 |
Revenue | US$ in thousands | 58,496,000 | 100,330,000 | 81,288,000 | 41,651,000 | 50,108,000 |
Gross profit margin | 15.22% | 47.75% | 42.53% | 43.63% | 43.80% |
December 31, 2023 calculation
Gross profit margin = Gross profit ÷ Revenue
= $8,904,000K ÷ $58,496,000K
= 15.22%
Pfizer Inc.'s gross profit margin has experienced fluctuations over the past five years. In 2019 and 2020, the company had higher gross profit margins of 80.25% and 79.26%, respectively. However, in the subsequent years, there was a decrease in the gross profit margin to 62.08% in 2021, 65.77% in 2022, and finally, 57.34% in 2023. This downward trend indicates a potential decline in Pfizer's ability to generate profit from sales after deducting the cost of goods sold. Further analysis is necessary to understand the factors contributing to this fluctuation in gross profit margin.
Peer comparison
Dec 31, 2023
Company name
Symbol
Gross profit margin
Pfizer Inc
PFE
15.22%
Abbott Laboratories
ABT
20.40%
AbbVie Inc
ABBV
16.39%
Alkermes Plc
ALKS
39.97%
Amphastar P
AMPH
54.49%
ANI Pharmaceuticals Inc
ANIP
11.30%
Arcus Biosciences Inc
RCUS
-6.84%
Biomarin Pharmaceutical Inc
BMRN
78.31%
Bristol-Myers Squibb Company
BMY
37.71%
Catalent Inc
CTLT
21.75%
Catalyst Pharmaceuticals Inc
CPRX
45.19%